PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Gliclazide - Diabetes Mellitus

PAD Profile : Gliclazide - Diabetes Mellitus

Keywords :
sulphonylureas, Blood Glucose Lowering drug, Type II
Brand Names Include :
Diamicron, Zicron, Glydex, Edicil, Lamzarin, Exywin, Ziclaseg

Traffic Light Status

Status 1 of 2.

Status :
Green
Preferred
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Green (see narrative)
Important
Formulations :
  • Modified release
Important Information :
Immediate release tablets are preferred
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 February 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
THE PREFERRED SULFONYLUREA: Appropriate for initiation in primary care and/or continued in primary care following a recommendation from specialists in other health care sectors. PRESCRIBE GENERICALLY - NOTE - the branded product, Diamicron, was considered BLACK at the PCN in May 2017.

Associated BNF Codes

06. Endocrine System
06.01.02. Antidiabetic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More